Tavio Capital LLC acquired a new stake in shares of Teladoc, Inc. (NYSE:TDOC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 210,011 shares of the health services provider’s stock, valued at approximately $7,287,000. Teladoc accounts for 3.6% of Tavio Capital LLC’s investment portfolio, making the stock its 8th largest position. Tavio Capital LLC owned approximately 0.39% of Teladoc at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in TDOC. US Bancorp DE increased its stake in shares of Teladoc by 10.3% in the first quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock worth $116,000 after buying an additional 433 shares during the period. Jaffetilchin Investment Partners LLC boosted its position in Teladoc by 1.8% in the first quarter. Jaffetilchin Investment Partners LLC now owns 45,225 shares of the health services provider’s stock worth $1,131,000 after buying an additional 814 shares in the last quarter. Teachers Advisors LLC boosted its position in Teladoc by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 35,205 shares of the health services provider’s stock worth $581,000 after buying an additional 1,759 shares in the last quarter. Bank of Montreal Can boosted its position in Teladoc by 214.2% in the second quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock worth $123,000 after buying an additional 2,397 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in Teladoc by 66.3% in the first quarter. Legal & General Group Plc now owns 6,137 shares of the health services provider’s stock worth $154,000 after buying an additional 2,446 shares in the last quarter. 94.51% of the stock is owned by institutional investors and hedge funds.
Shares of Teladoc, Inc. (NYSE:TDOC) opened at 29.50 on Friday. Teladoc, Inc. has a 12 month low of $14.00 and a 12 month high of $36.90. The stock’s market capitalization is $1.67 billion. The stock’s 50 day moving average is $33.13 and its 200 day moving average is $27.90.
Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.02. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The company had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. During the same period last year, the company earned ($0.38) earnings per share. The business’s revenue for the quarter was up 68.3% compared to the same quarter last year. Analysts anticipate that Teladoc, Inc. will post ($1.44) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was reported by BNB Daily and is the property of of BNB Daily. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/tavio-capital-llc-acquires-shares-of-210011-teladoc-inc-nysetdoc-updated-updated.html.
TDOC has been the topic of a number of recent research reports. Zacks Investment Research cut Teladoc from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Piper Jaffray Companies reissued a “buy” rating and issued a $42.00 target price on shares of Teladoc in a research note on Friday, July 28th. Cowen and Company raised their price objective on shares of Teladoc from $29.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday, May 31st. BidaskClub lowered shares of Teladoc from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Finally, Robert W. Baird reiterated a “buy” rating and set a $28.00 target price on shares of Teladoc in a report on Tuesday, May 9th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $35.55.
In related news, CEO Jason N. Gorevic sold 5,600 shares of the stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $29.57, for a total value of $165,592.00. Following the sale, the chief executive officer now directly owns 823,861 shares of the company’s stock, valued at approximately $24,361,569.77. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Jason N. Gorevic sold 19,991 shares of the firm’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $32.89, for a total transaction of $657,503.99. Following the completion of the transaction, the chief executive officer now owns 831,650 shares in the company, valued at approximately $27,352,968.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 107,186 shares of company stock worth $3,352,950. 5.94% of the stock is owned by corporate insiders.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.